Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To evaluate the effect of nilotinib on pulmonary vascular resistance (PVR) compared to placebo after 24 weeks of therapy
Critère d'inclusion
- Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy